$37.48 0.00 (0.00%)

Royalty Pharma plc Class A Ordinary Shares (RPRX)

Royalty Pharma plc (RPRX) is a pharmaceutical royalty financial company that acquires royalties from commercialized medicines, biotechnological innovations, and research and development programs. Established as a leading player in the royalty monetization sector, it provides capital to biopharmaceutical companies and researchers while generating revenue from the royalties it holds on successful drug sales.

Dividend Yield 2.35%
Payout Frequency Quarterly

Dividend History

🎉 Upcoming Dividend

Investors can expect a dividend payout of $0.22 per share, scheduled to be distributed in 49 days on December 10, 2025

Pay DateAmountEx-DateRecord Date
December 10, 2025$0.222025-11-142025-11-14
September 10, 2025$0.222025-08-152025-08-15
June 10, 2025$0.222025-05-162025-05-16
March 10, 2025$0.222025-02-212025-02-21
December 10, 2024$0.212024-11-152024-11-15

Dividends Summary

Company News

Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes
GlobeNewswire Inc. • Royalty Pharma • September 3, 2025

Royalty Pharma announced a $2.0 billion senior unsecured notes offering with three tranches: $600 million due 2031, $900 million due 2035, and $500 million due 2055. The proceeds will be used for general corporate purposes.

Royalty Pharma to Acquire Royalty Interest in Amgen's Imdelltra for up to $950 Million
Benzinga • Globe Newswire • August 25, 2025

Royalty Pharma will acquire a royalty interest in Amgen's Imdelltra, a first-in-class immunotherapy for extensive-stage small cell lung cancer, for $885 million upfront with an additional potential $65 million option from BeOne Medicines.

3 High-Yield Dividend Stocks to Buy in 2025 and Hold for a Decade or Longer
The Motley Fool • Cory Renauer • December 13, 2024

The article discusses three dividend-paying stocks - Royalty Pharma, W.P. Carey, and Omega Healthcare Investors - that have seen their stock prices fall recently but offer attractive dividend yields. The author believes these stocks could be good additions to a diversified portfolio.

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
Zacks Investment Research • Zacks Equity Research • June 18, 2024

Sector ETF report for IHE